GlassScriptPhysician profile
Deborah A Needle
NPI 1225097835
$1,033.96
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.06 · 2022: $541 · 2023: $258 · 2024: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $453.76 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $185.05 | 2024 | Korlym |
| Boston Scientific Corporation | $143.13 | 2022 | |
| Nevro Corp. | $140.66 | 2022 | |
| Novo Nordisk INC | $116.52 | 2022 | |
| Abbvie INC. | $95.68 | 2023 | |
| Myovant Sciences INC. | $87.70 | 2022 | |
| Shield Therapeutics INC | $84.40 | 2023 | Accrufer |
| Idorsia Pharmaceuticals US INC | $44.60 | 2023 | Quviviq |
| Lilly USA, LLC | $41.72 | 2022-2024 | Zepbound |
| Organon LLC | $19.73 | 2022 | |
| Currax Pharmaceuticals LLC | $17.13 | 2023 | Contrave |
| Astellas Pharma US INC | $16.15 | 2023 | Veozah |
| Genentech USA, INC. | $16.12 | 2021 | |
| Horizon Therapeutics Plc | $13.43 | 2022 | |
| Paratek Pharmaceuticals, INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Needle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.